The dual PPAR-α/δagonist elafibranor (GFT505) has demonstrated efficacy in preclinical models of NAFLD, NASH, and liver fibrosis (Staels et al., 2013). Here, PPARA is linked to metabolic dysfunction-associated steatotic liver disease.